Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

Autores
Ridruejo, Ezequiel; Mendizabal, Manuel; Silva, Marcelo O.
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
Fil: Mendizabal, Manuel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
Fil: Silva, Marcelo O.. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
Materia
CHRONIC KIDNEY DISEASE STAGES 2 TO 3
DIRECT-ACTING ANTIVIRAL AGENTS
HEPATITIS C VIRUS INFECTION
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/86460
Acceder
id CONICETDig_472e6e48ac80ef41b404b940ace1f435
oai_identifier_str oai:ri.conicet.gov.ar:11336/86460
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney diseaseRidruejo, EzequielMendizabal, ManuelSilva, Marcelo O.CHRONIC KIDNEY DISEASE STAGES 2 TO 3DIRECT-ACTING ANTIVIRAL AGENTSHEPATITIS C VIRUS INFECTIONTREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; ArgentinaFil: Mendizabal, Manuel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; ArgentinaFil: Silva, Marcelo O.. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; ArgentinaWiley Blackwell Publishing, Inc2018-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/86460Ridruejo, Ezequiel; Mendizabal, Manuel; Silva, Marcelo O.; Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease; Wiley Blackwell Publishing, Inc; Hemodialysis International; 22; 4-2018; S97-S1031492-7535CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/hdi.12651info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/hdi.12651info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:46:14Zoai:ri.conicet.gov.ar:11336/86460instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:46:14.727CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
title Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
spellingShingle Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
Ridruejo, Ezequiel
CHRONIC KIDNEY DISEASE STAGES 2 TO 3
DIRECT-ACTING ANTIVIRAL AGENTS
HEPATITIS C VIRUS INFECTION
TREATMENT
title_short Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
title_full Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
title_fullStr Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
title_full_unstemmed Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
title_sort Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
dc.creator.none.fl_str_mv Ridruejo, Ezequiel
Mendizabal, Manuel
Silva, Marcelo O.
author Ridruejo, Ezequiel
author_facet Ridruejo, Ezequiel
Mendizabal, Manuel
Silva, Marcelo O.
author_role author
author2 Mendizabal, Manuel
Silva, Marcelo O.
author2_role author
author
dc.subject.none.fl_str_mv CHRONIC KIDNEY DISEASE STAGES 2 TO 3
DIRECT-ACTING ANTIVIRAL AGENTS
HEPATITIS C VIRUS INFECTION
TREATMENT
topic CHRONIC KIDNEY DISEASE STAGES 2 TO 3
DIRECT-ACTING ANTIVIRAL AGENTS
HEPATITIS C VIRUS INFECTION
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
Fil: Mendizabal, Manuel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
Fil: Silva, Marcelo O.. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina
description Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.
publishDate 2018
dc.date.none.fl_str_mv 2018-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/86460
Ridruejo, Ezequiel; Mendizabal, Manuel; Silva, Marcelo O.; Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease; Wiley Blackwell Publishing, Inc; Hemodialysis International; 22; 4-2018; S97-S103
1492-7535
CONICET Digital
CONICET
url http://hdl.handle.net/11336/86460
identifier_str_mv Ridruejo, Ezequiel; Mendizabal, Manuel; Silva, Marcelo O.; Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease; Wiley Blackwell Publishing, Inc; Hemodialysis International; 22; 4-2018; S97-S103
1492-7535
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1111/hdi.12651
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/hdi.12651
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268779734630400
score 13.13397

Publicaciones similares